Novarous China President Yu Xudong will leave office

Most of the year 2020 has passed, almost every month MNC announced personnel changes, a closer look at MNC's actions in recent years, you can see that the patent cliff, research and development innovation under the dual pressure of strategic adjustment may be behind the reasons.
and domestic policies and capital are both good for the development of innovative drugs, local biotech development also urgently needs to have mature experience of senior executives.
just last August, the most unexpected MNC personnel change was the confirmation of the departure of Geely's general manager for China, Luo Yongqing.
and just after September, the MNC announced another heavyweight personnel change: Novarma Pharmaceuticals China President Yu Xudong will leave Novarma.
afternoon of September 4, Novarma announced to employees that Novarma Pharmaceuticals Asia Pacific, Middle East and Africa (APMA) President and Novaral Group China President Yu Xudong had decided to leave Novarma for personal reasons.
, Dan Brindle will take over as President of Novaral China and Iris Zemzoum will take over as President of the Asia Pacific, Middle East and Africa Region (APMA).
personnel changes at Novarth and Gilead are not uncommon in the first half of 2020.
, according to E-Drug Manager incomplete statistics, so far in 2020, in addition to the above two, there have been GE Healthcare, Bayer, BMS, Mercator and other multinational MNC announced personnel changes.
01 The continuation of strategic change looks back on previous years, there is always a wave of multinational pharmaceutical companies leaving, this year is no different, but this year's influence factors have one more: the new crown epidemic pandemic.
the impact of the new crown outbreak on multinational MNCs is to catalyz layoffs, splits and restructurings.
February, Mercedon announced that it would begin divesting its women's health products, mature products and biosimilar products, created a new independent public company, and the same month, GSK announced a two-year spin-off that will focus on the immune system and consumer health. In May, AbbVie announced the completion of a $63 billion acquisition of AerGe, and in July, Sanofi announced plans to cut more than 1,700 jobs in Europe and about 1,000 in France over the next three years.
a two-year restructuring plan to lay off 720 employees, and in August Bayer announced that it was divesting its active insurance business and mestring the company. In fact, these adjustments are a continuation of the business and strategic changes that have taken place across MNC in recent years, where the outbreak has played a catalyser role.
according to IQVIA's 2019 Review of Mergers and Acquisitions in the Global Pharmaceutical Market, the average number of mergers and acquisitions and cooperative transactions in the global life sciences sector rose in 2019, with annual mergers and acquisitions of $293 billion, up 43% from 2018.
, such as patent cliff, medical insurance reimbursement, research and development costs and other crises put pressure on the performance of multinational MNCs, multinational MNCs urgently need to find new growth points.
therefore, through mergers and acquisitions to expand the research and development pipeline, through the split of non-core business, "plus and minus" has become a multinational MNC to seek to develop the new logic, and personnel adjustment is one of the steps.
AbbVie and Aljian acquired Aer Jian Aesthetics, and wang Weisheng, former president of Aljian China, was promoted to vice president of Aer Jian Aesthetics and head of Japan and asia-Pacific, a personnel change that is typical.
AbbVie's home product, "Drug King", has long been the main driver of AbbVie's growth, leading the global drug sales list for many years, but the patent cliff is also falling, Sebel has expired patents in the United States and Europe in 2016 and 2018, respectively, AbbVie's demand for new heavy drugs is growing.
acquisition of Aer Jian, the establishment of Aer Jian aesthetic is naturally one of the layout of AbbVie's expanded product pipeline.
merger and acquisition split, expansion of product pipeline with personnel adjustment, cross-border MNC to open a new stage of development may also be one of the reasons.
example of this is Gilead China.
August, the news of Gilead's departure from china caused a stir in the industry, but it may also come as a surprise to watch Gilead's performance in recent years.
joined Gilead in 2016 with the primary goal of forming Gilead's China business team, which currently has more than 450 employees, a goal that has clearly been achieved.
and Luo Yongqing's other important goal is to promote the launch of heavyweights Sovaldi, Haroni, Epclusa and TF in China, a goal that is clearly achieved.
a total of eight innovative drugs have been approved in China, including four drugs such as Weilid, Proponza, Xia Fanning and JetFluen, which have been included in health insurance in just one year.
it has been nearly five years since Mr Gilliard entered China, and the first five-year plan is now largely complete, Mr Luo's departure may be to be expected.
02 The reason for another personnel change in the local innovation pharmaceutical enterprises may not be related to the change of the domestic innovation environment.
"4 plus 7" collection and other policies to accelerate the transformation of local pharmaceutical companies to innovative drugs direction, the Hong Kong Stock Exchange new regulations, science and technology board opening board and other capital to encourage local biotech enterprises to finance, "policy and capital" dual holding, local innovative pharmaceutical enterprises ushered in a major outbreak.
and innovative pharmaceutical companies in both research and development and operations are in dire need of talent, with mature experience of multinational MNC executives have become innovative pharmaceutical companies to tap talent.
In March this year, Shanghai Alice Pharmaceuticals announced the appointment of Mu Yanping as CEO, after Mu Yanping founded the Merca East China Oncology Division and served as the head, under the leadership of Mu Yanping Merca East China Oncology Division successfully ranked among the top three foreign pharmaceutical companies in the oncology business.
May, 1 Pharmaceutical Network announced the appointment of Guo Anfeng as Chief Innovation Officer, Guo Anfeng served as Vice President of BMS China's Immuno-Oncology Division, and Guo Anfeng founded BMS' first immuno-oncology sales team in China.
multinational pharmaceutical companies to "return to the core business", domestic pharmaceutical companies get the dual power of capital and policy, whether local biotech or multinational MNC, innovation is undoubtedly the direction of development, research and development and management personnel are also facing choices.
original title: Novart China president will leave, multinational MNC in January an executive left, domestic innovative pharmaceutical companies and multinational pharmaceutical companies "talent war" or will come?